A single-arm, open, exploratory clinical study to evaluate the safety, tolerance and preliminary efficacy of mesenchymal stem cells (umbilical cord) for injection in patients with acute respiratory distress syndrome (ARDS) caused by infection

Start Date06 May 2023

Sponsor / Collaborator

China-Japan Friendship Hospital

ChiCTR2200056751 / SuspendedPhase 1IIT

Clinical study on the safety and efficacy of in-situ ovarian injection of umbilical cord mesenchymal stem cells in the treatment of premature ovarian insufficiency

Start Date15 Dec 2021

Sponsor / Collaborator

Sir Run Run Shaw Hospital

ChiCTR2100047110 / RecruitingNot ApplicableIIT

A prospective clinical controlled study evaluating the effectiveness and safety of umbilical cord mesenchymal stem cells in the treatment of decompensated liver cirrhosis

Start Date01 Sep 2021

Sponsor / Collaborator-

100 Clinical Results associated with Omidubicel (Gamida Cell)

100 Translational Medicine associated with Omidubicel (Gamida Cell)

100 Patents (Medical) associated with Omidubicel (Gamida Cell)

Literatures (Medical) associated with Omidubicel (Gamida Cell)

01 Dec 2023·Transplantation and cellular therapy

Hospitalization and Healthcare Resource Utilization of Omidubicel-Onlv versus Umbilical Cord Blood Transplantation for Hematologic Malignancies: Secondary Analysis from a Pivotal Phase 3 Clinical Trial

Article

Author: Manghani, Rocio ; Miller, Beckley ; Dean, Rebecca ; Maziarz, Richard T ; Majhail, Navneet S ; Sivaraman, Smitha ; Shin, Heayoung

A phase 3 trial (ClincialTrials.gov identifier NCT02730299) of omidubicel-onlv, a nicotinamide-modified allogeneic hematopoietic progenitor cell therapy manufactured from a single umbilical cord blood (UCB) unit, showed faster hematopoietic recovery, reduced rate of infections, and shorter hospital stay compared with patients randomized to standard UCB. This prospective secondary analysis of the phase 3 trial characterized resource utilization in the first 100 days post-transplantation with omidubicel-onlv compared with UCB. This analysis examined resource utilization, including hospital length of stay, hospital care setting, visits by provider type, rate of transfusions, and readmissions, among the 108 treated patients (omidubicel-onlv, n = 52; UCB, n = 56) from day 0 to day 100 post-transplantation. Demographics were generally balanced between the 2 arms, except a higher proportion of females (52% versus 37%) and older median age (40 years versus 36 years) were noted in the omidubicel-onlv arm. Compared with patients receiving UCB transplantation, patients receiving omidubicel-onlv had a shorter average total hospital length of stay (mean, 41.2 days versus 50.8 days; P = .027) in the first 100 days post-transplantation and more days alive and out of the hospital (mean, 55.8 days versus 43.7 days; P = .023). Fewer patients died in the omidubicel-onlv arm compared with the UCB arm (12% vs 16%) before day 100 post-transplantation. During primary hospitalization (ie, time from transplantation to discharge), fewer patients receiving omidubicel-onlv required intensive care unit (ICU) admission (10% versus 23%) and spent fewer days in the ICU (mean, .4 day versus 4.7 days; P = .028) and transplant unit (mean, 25.3 days versus 32.9 days; P = .022) compared with those receiving UCB. Patients receiving omidubicel-onlv required fewer outpatient consultant and nonconsultant visits and fewer platelet or other transfusions within 100 days from transplantation. Our findings suggest that faster hematopoietic recovery in omidubicel-onlv patients is associated with significantly shorter hospital stay and reduced healthcare resource use compared with UCB.

01 Sep 2023·Molecular diagnosis & therapy

Omidubicel: First Approval.

Review

Author: Heo, Young-A

Omidubicel (omidubicel-onlv; Omisirge^®) is a nicotinamide-modified stem cell graft derived from cord blood that is being developed by Gamida Cell for the treatment of haematological malignancies and haemoglobinopathies. In April 2023, omidubicel received its first approval in the USA for use in adults and children aged ≥ 12 years with haematological malignancies who are planned for cord blood transplantation following myeloablative conditioning to reduce the incidence of infection and the time to neutrophil recovery. This article summarizes the milestones in the development of omidubicel leading to this first approval.

01 Aug 2023·Transplantation and cellular therapy

Immune Reconstitution Profiling Suggests Antiviral Protection after Transplantation with Omidubicel: A Phase 3 Substudy.

Article

Author: Keating, Amy ; Hanna, Rabi ; Karras, Nicole ; Szabolcs, Paul ; Mazor, Roei D ; Hamerschlak, Nelson ; McGuirk, Joseph ; Horwitz, Mitchell E ; López-Torija, Ivan ; Yackoubov, Dima ; Levy, Stuart ; Sanz, Guillermo ; Lindemans, Caroline A ; Rezvani, Andrew ; Stiff, Patrick ; Wagner, John ; Valcarcel, David

Allogeneic hematopoietic cell transplantation (HCT) is a potentially curative treatment for hematologic malignancies and nonmalignant disorders. Rapid immune reconstitution (IR) following allogeneic HCT has been shown to be associated with improved clinical outcomes and lower infection rates. A global phase 3 trial (ClinicalTrials.gov NCT02730299) of omidubicel, an advanced cell therapy manufactured from an appropriately HLA-matched single umbilical cord blood (UCB) unit, showed faster hematopoietic recovery, reduced rates of infection, and shorter hospitalizations in patients randomized to omidubicel compared with those randomized to standard UCB. This optional, prospective substudy of the global phase 3 trial characterized the IR kinetics following HCT with omidubicel compared with UCB in a systematic and detailed manner. This substudy included 37 patients from 14 global sites (omidubicel, n = 17; UCB, n = 20). Peripheral blood samples were collected at 10 predefined time points from 7 to 365 days post-HCT. Flow cytometry immunophenotyping, T cell receptor excision circle quantification, and T cell receptor sequencing were used to evaluate the longitudinal IR kinetics post-transplantation and their association with clinical outcomes. Patient characteristics in the 2 comparator cohorts were overall statistically similar except for age and total body irradiation (TBI)-based conditioning regimens. The median patient age was 30 years (range, 13 to 62 years) for recipients of omidubicel and 43 years (range, 19 to 55 years) for UCB recipients. A TBI-based conditioning regimen was used in 47% of omidubicel recipients and in 70% of UCB recipients. Graft characteristics differed in their cellular composition. Omidubicel recipients received a 33-fold higher median dose of CD34⁺ stem cells and one-third of the median CD3⁺ lymphocyte dose infused to UCB recipients. Compared with UCB recipients, omidubicel recipients exhibited faster IR of all measured lymphoid and myelomonocytic subpopulations, predominantly in the first 14 days post-transplantation. This effect involved circulating natural killer (NK) cells, helper T (Th) cells, monocytes, and dendritic cells, with superior long-term B cell recovery from day +28. At 1 week post-HCT, omidubicel recipients exhibited 4.1- and 7.7 -fold increases in the median Th cell and NK cell counts, respectively, compared to UCB recipients. By 3 weeks post-HCT, omidubicel recipients were 3-fold more likely to achieve clinically relevant Th cell and NK cell counts ≥100 cells/µL. Similar to UCB, omidubicel yielded a balanced cellular subpopulation composition and diverse T cell receptor repertoire in both the short term and the long term. Omidubicel's CD34⁺ cell content correlated with faster IR by day +7 post-HCT, which in turn coincided with earlier hematopoietic recovery. Finally, early NK and Th cell reconstitution correlated with a decreased rate of post-HCT viral infections, suggesting a plausible explanation for this phenomenon among omidubicel recipients in the phase 3 study. Our findings suggest that omidubicel efficiently promotes IR across multiple immune cells, including CD4⁺ T cells, B cells, NK cells, and dendritic cell subtypes as early as 7 days post-transplantation, potentially endowing recipients of omidubicel with early protective immunity.

News (Medical) associated with Omidubicel (Gamida Cell)

18 Jun 2024

·www.biospace.com

Gamida Cell Announces New Leadership Under Ownership of Highbridge Capital Management

Stem-cell innovator poised to advance the commercialization of its cancer treatment, with $30 million of initial new capital and access to substantial additional funds to drive growth Experienced management team joins company, with more than 80 years of cumulative experience expanding access to innovative treatments for the patients who need them most BOSTON--(BUSINESS WIRE)-- Gamida Cell Ltd. (the “Company”), a cell therapy pioneer working to turn cells into powerful therapeutics, today announced new executive leadership following a successful restructuring transaction ("Transaction”) with certain funds managed by Highbridge Capital Management, LLC (collectively, “Highbridge”) on May 24, 2024. As part of the Transaction, Highbridge invested $30 million of new capital into Gamida Cell, and is expected to provide substantial additional capital to support ongoing operations, including the research and development, manufacturing, and commercialization of its cell therapeutics. Following the Transaction, Gamida Cell now operates as a wholly owned subsidiary of Ayrmid Limited, a UK entity. To advance the commercialization of Omisirge® (omidubicel-onlv), a NAM-modified cell therapy for allogenic hematopoietic stem cell transplant, Gamida Cell has named industry stalwart Dr. Joe Wiley as Chief Executive Officer, Rory Nealon as Chief Financial Officer, and Sheila Frame as Chief Commercial Officer. “Gamida Cell has made great strides in advancing potentially curative cell therapies for cancer and has demonstrated the tremendous potential of its life-saving therapies to improve prospects for patients who cannot find appropriate donors,” said Wiley. “With Highbridge's support, I look forward to leading Gamida Cell into its next phase as we work with hospitals across the U.S. to expand access to Omisirge for the patients who need it most." Wiley, Nealon, and Frame collectively bring more than 80 years of experience in building, growing, and commercializing innovative pharmaceutical treatments globally: Dr. Joe Wiley founded Amryt Pharma and served as the CEO until it was acquired by Chiesi Farmaceutici in April 2023. Prior to his role at Amryt, Wiley served as the Principal at Sofinnova Ventures and Medical Director at Astellas Pharma, and he held multiple investment management roles following his work as a neurologist. Rory Nealon was the co-founder, Chief Financial and Operating Officer at Amryt Pharma from 2015 through its acquisition in 2023. Before joining Amryt, he served executive roles at Trinity Biotech, first as the Chief Financial Officer then as the Chief Operations Officer. Sheila Frame most recently served as President Americas of Amryt Pharma until it’s sale to the Chiesi Farmaceutici in 2023. Frame has spent much of her career in executive positions leading the commercialization and growth of several important pharmaceutical products in oncology, immunology, and rare diseases in the US as well as globally. “Through our recent transaction and infusion of new capital, we are demonstrating our commitment to supporting this mission-driven company as it works toward broadening the availability of its critically important treatment,” said Jonathan Segal, Co-Chief Investment Officer at Highbridge. “We thank Gamida’s prior management team for their dedication in advancing Omisirge and we look forward to a productive collaboration with the newly appointed leadership team to drive Gamida Cell’s future success.” About Gamida Cell Gamida Cell is a cell therapy pioneer working to turn cells into powerful therapeutics. The company’s proprietary nicotinamide (NAM) technology leverages the properties of NAM to enhance and expand cells, creating allogeneic cell therapy products and candidates that are potentially curative for patients with hematologic malignancies. These include Omisirge® (omidubicel-onlv), an FDA-approved nicotinamide modified allogeneic hematopoietic progenitor cell therapy, and GDA-201, an intrinsic NK (natural killer) cell therapy candidate being investigated for the treatment of hematologic malignancies. Gamida Cell operates as a wholly owned subsidiary of Ayrmid Limited, a UK entity. For additional information, please visit or follow Gamida Cell on LinkedIn, X, Facebook or Instagram. About Highbridge Capital Management Founded in 1992, Highbridge Capital Management, LLC (“Highbridge”) is a global alternative investment firm offering differentiated credit and volatility focused solutions across a range of liquidity and investment pro including hedge funds, drawdown vehicles, and co-investments. The firm seeks to generate attractive risk-adjusted returns for sophisticated investors, which include financial institutions, public and corporate pension funds, sovereign wealth funds, endowments and family offices. Highbridge is headquartered in New York, with a research presence in London. In 2004 Highbridge established a strategic partnership with J.P. Morgan. Highbridge has over $4 billion in assets under management, as of April 1, 2024, and holds meaningful investments across the global healthcare and life sciences spectrum.

Cell TherapyAcquisitionExecutive Change

29 Mar 2024

·www.biospace.com

Gamida Restructures Under Ownership of Highbridge Capital Management

Pictured: 3D illustration of arrows reflecting changes in direction/iStock/Olivier Le Moal Despite having an FDA-approved product, Gamida Cell is entering into a restructuring agreement in which it will become a private company under the ownership of Highbridge Capital Management amid financial struggles, the company announced Wednesday. Under the agreement, Gamida Cell will become a private company wholly owned by Highbridge Capital Management—the biotech’s principal lender. The move is designed to give the company some long-term runway and support the commercialization of Omisirge, an FDA-approved nicotinamide modified allogeneic hematopoietic progenitor cell therapy. This comes after the biotech announced in January that it was seeking “strategic alternatives” and was focused on an asset sale, merger, or other deal. “In March 2023, Gamida Cell embarked on an extensive strategic process to address its capital structure and liquidity constraints by partnering Omisirge with a third party,” Gamida Cell CEO Abbey Jenkins said in Wednesday’s statement. “Unfortunately, that process did not yield any actionable alternatives. This restructuring will enable Gamida Cell to remain a going concern. It will support our ongoing efforts to make Omisirge available to more transplant centers and their patients as a potentially lifesaving donor source option.” The terms of the restructuring will see Highbridge convert $75 million of its existing unsecured convertible senior note into equity for Gamida Cell. The biotech will also get $30 million of new capital from Highbridge when the restructuring goes into effect. The biotech will now be off the stock market and wholly owned by Highbridge, with all ordinary shares expected to be canceled. The reorganized Gamida Cell will also issue contingent value rights with a maximum value of $27.5 million to shareholders. Gamida Cell’s main product, Omisirge, was approved by the FDA in April 2023 after a lengthy regulatory road and is indicated for patients who are scheduled to undergo umbilical cord blood transplantation after chemotherapy or radiotherapy. However, the therapy does come with a boxed warning for potentially fatal conditions such as infusion reactions, graft failure, engraftment syndrome, and graft-versus-host disease. The company revealed in a third-quarter report in 2023 that 17 transplant centers were onboarded to provide Omisirge to patients, exceeding the company’s target of 10 to 15. However, the company said that it would continue to have a “lean launch effort” in 2024 due to “resource constraints” and—contingent on additional funding to extend its cash runway—would plan to onboard at least 40 transplant centers by the end of this year. “Despite Gamida Cell’s financial struggles, we believe in the potential of Omisirge to fulfill an important unmet need in stem cell transplant,” Jonathan Segal, co-chief investment officer at Highbridge Capital Management, said in a statement. “Subject to an approved budget from the Company’s new board of directors, we intend to provide the Company with additional capital to fund this potentially life-saving therapy.” The deal is expected to close in the second quarter of 2024 upon being approved by an Israeli court. Tyler Patchen is a staff writer at BioSpace. You can reach him at tyler.patchen@biospace.com. Follow him on LinkedIn.

Cell TherapyDrug ApprovalImmunotherapyAcquisition

27 Mar 2024

·www.globenewswire.com

Gamida Cell Announces Commencement of Restructuring Process Supported by Highbridge Capital Management

Company expected to receive significant new capital from Highbridge to bolster the commercialization of allogeneic stem cell transplant Omisirge® (omidubicel-onlv) Gamida Cell to become a private company under ownership of Highbridge following Israeli court approval BOSTON and NEW YORK, March 27, 2024 (GLOBE NEWSWIRE) -- Gamida Cell Ltd. (Nasdaq: GMDA), a cell therapy pioneer working to turn cells into powerful therapeutics, today announced that it has entered into a Restructuring Support Agreement (the “RSA” or “transaction”) with certain funds managed by Highbridge Capital Management, LLC (“Highbridge”), the Company’s principal lender. The transaction is anticipated to provide Gamida Cell with a long-term financial runway and support the ongoing commercialization of Omisirge® (omidubicel-onlv) and is expected to be completed through a voluntary Israeli restructuring proceeding. “In March 2023, Gamida Cell embarked on an extensive strategic process to address its capital structure and liquidity constraints by partnering Omisirge with a third party,” said Abbey Jenkins, President and Chief Executive Officer of Gamida Cell. “Unfortunately, that process did not yield any actionable alternatives. This restructuring will enable Gamida Cell to remain as a going concern and will support our ongoing efforts to make Omisirge available to more transplant centers and their patients as a potentially lifesaving donor source option.” Contemplated under the terms of the RSA, and upon closing: Highbridge will convert $75 million of its existing unsecured convertible senior note into equity in the Company.The Company will receive $30 million of new capital from Highbridge on the effective date of the restructuring. This capital infusion, along with additional capital expected to be invested by Highbridge following the Company’s emergence, should position the Company to meet its goals around the commercialization of Omisirge.Gamida Cell will become a private company, wholly owned by Highbridge, and the Company’s outstanding ordinary shares are expected to be canceled.The newly reorganized Gamida Cell will issue contingent value rights with a potential aggregate maximum value of $27.5 million to holders of Gamida Cell’s ordinary shares, subject to the achievement of certain revenue and regulatory milestones within specified time frames. “Despite Gamida Cell’s financial struggles, we believe in the potential of Omisirge to fulfill an important unmet need in stem cell transplant,” said Jonathan Segal, Co-Chief Investment Officer at Highbridge Capital Management. “Subject to an approved budget from the Company’s new board of directors, we intend to provide the Company with additional capital to fund this potentially life-saving therapy. We are hopeful that our continued support of the Company will allow Omisirge to be available for those who need it.” The Company expects the transaction to close in the second quarter following approval by the Israeli court. AdvisorsMoelis & Company LLC is serving as financial advisor, Cooley LLP is serving as U.S. legal counsel, and Meitar | Law Offices is serving as Israeli legal counsel to Gamida Cell. King & Spalding LLP is serving as U.S. legal counsel and Herzog Fox & Neeman is serving as Israeli legal counsel to Highbridge. About Gamida Cell Gamida Cell is a cell therapy pioneer working to turn cells into powerful therapeutics. The company’s proprietary nicotinamide (NAM) technology leverages the properties of NAM to enhance and expand cells, creating allogeneic cell therapy products and candidates that are potentially curative for patients with hematologic malignancies. These include Omisirge® (omidubicel-onlv), an FDA-approved nicotinamide modified allogeneic hematopoietic progenitor cell therapy, and GDA-201, an intrinsic NK (natural killer) cell therapy candidate being investigated for the treatment of hematologic malignancies. For additional information, please visit www.gamida-cell.com or follow Gamida Cell on LinkedIn, X, Facebook or Instagram. Cautionary Note Regarding Forward-Looking Statements This press release contains forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995. Any statement describing Gamida Cell’s goals, expectations, financial or other projections, intentions or beliefs is a forward-looking statement and should be considered an at-risk statement. Such statements, including those with respect to the curative therapeutic and commercial potential of Omisirge® (omidubicel-onlv), continued commercialization of and patient access to Omisirge® (omidubicel-onlv), financial runway of Gamida Cell, Gamida Cell’s ability to complete a transaction supported by Highbridge pursuant to the RSA, and Gamida Cell’s ability to secure the Israeli court’s approval of the transaction are subject to a number of risks, uncertainties and assumptions. These risks, uncertainties and assumptions include those related to clinical, scientific, regulatory and technical developments and those inherent in the process of developing and commercializing product candidates that are safe and effective for use as human therapeutics, and as to the pursuit of the transactions contemplated under the RSA, the risk that no transaction may result. In light of these risks and uncertainties, and other risks and uncertainties that are described in the Risk Factors section and other sections of Gamida Cell’s Annual Report on Form 10-K filed with the Securities and Exchange Commission (SEC) on March 27, 2024, and other filings that Gamida Cell makes with the SEC from time to time (which are available at www.sec.gov), the events and circumstances discussed in such forward-looking statements may not occur, and Gamida Cell’s actual results could differ materially and adversely from those anticipated or implied thereby. Although Gamida Cell’s forward-looking statements reflect the good faith judgment of its management, these statements are based only on facts and factors currently known by Gamida Cell. As a result, you are cautioned not to rely on these forward-looking statements. OMISIRGE® is a registered mark of Gamida Cell Ltd. © 2024 Gamida Cell Ltd. All Rights Reserved. Contacts Investors Chuck Padala  LifeSci Advisors  Chuck@lifesciadvisors.com 1-646-627-8390  Media Mike Kuczkowski Orangefierymedia@orangefiery.com917-865-3213 For Highbridge Capital Managementpress@highbridge.com

Cell TherapyImmunotherapy

100 Deals associated with Omidubicel (Gamida Cell)

R&D Status

Approved

10 top approved records.

to view more data

Indication	Country/Location	Organization	Date
Hematologic Neoplasms	US	Gamida Cell Ltd.	17 Apr 2023

Developing

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
acute leukemia	Phase 3	US	Gamida Cell Ltd.	16 Dec 2016
acute leukemia	Phase 3	BR	Gamida Cell Ltd.	16 Dec 2016
acute leukemia	Phase 3	FR	Gamida Cell Ltd.	16 Dec 2016
acute leukemia	Phase 3	IL	Gamida Cell Ltd.	16 Dec 2016
acute leukemia	Phase 3	IT	Gamida Cell Ltd.	16 Dec 2016
acute leukemia	Phase 3	NL	Gamida Cell Ltd.	16 Dec 2016
acute leukemia	Phase 3	PT	Gamida Cell Ltd.	16 Dec 2016
acute leukemia	Phase 3	SG	Gamida Cell Ltd.	16 Dec 2016
acute leukemia	Phase 3	ES	Gamida Cell Ltd.	16 Dec 2016
acute leukemia	Phase 3	GB	Gamida Cell Ltd.	16 Dec 2016

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT02730299 (Tandem Meetings ASTCT and CIBMTR2024) Manual	Phase 3	Hematologic Neoplasms	-	Omidubicel (EAP)	tbuzirntxe(vgwzaxiouo) = kfzvtdavqt vljazcasog (uayildedap ) View more	Positive	22 Feb 2024
				omidubicel (P3-OMI)	tbuzirntxe(vgwzaxiouo) = wmcfdmzbui vljazcasog (uayildedap ) View more
NCT02730299 (FDA) Manual	Phase 3	Hematologic Neoplasms	125	OMISIRGE	wjkqzcpsyh(syaldfddck) = vbfglmxppx mvdkemnqkv (drksrrmmpt, 10 - 15) View more	Superior	17 Apr 2023
				Umbilical Cord Blood	wjkqzcpsyh(syaldfddck) = jdiuchmqpm mvdkemnqkv (drksrrmmpt, 19 - 25) View more
NCT02730299 (Pubmed \| Circulation) Manual	Phase 3	Hematologic Neoplasms	125	Omidubicel	fijzeqyfds(lulwgnsofe) = fvqsermkdu echoduzkux (igpyrlyond, 10 ~ 14) View more	Positive	21 Oct 2021
				standard umbilical cord blood transplantation	fijzeqyfds(lulwgnsofe) = yzcjfkjtya echoduzkux (igpyrlyond, 19 ~ 25) View more
NCT01590628 (Pubmed) Manual	Phase 1/2	Anemia, Sickle Cell	-	Omidubicel (double cord blood)	gubkpsbkyv(kfuwiwrjol) = daxdypzsvr uybrlnaqyv (qadappumwm )	Positive	09 Feb 2021
				Omidubicel (single cord)	mvowqmlzny(wannxzavbc) = riompxxmta peiuoymily (uslsibfbly )
NCT01816230 (CTgov)	Phase 1/2	Myelodysplastic Syndromes \| Acute Myeloid Leukemia \| Acute Lymphoblastic Leukemia	36	NiCord®	ymbudfqozb(rbzheiisrx) = gontegxrxc igynzrsxiq (qutnvvzryi, dfqydhsypm - gohuwxchmy) View more	-	21 Sep 2020
NCT02504619 (CTgov)	Phase 1/2	Thalassemia \| Anemia, Sickle Cell	1	CordIn	fgxdfeblwq(nodnomigbg) = mcaisknylw mcrkntshut (ieewwjepek, bxaaycffby - gmzpaowzdi) View more	-	26 Jun 2019
NCT01816230 (Pubmed \| J Urol) Manual	Phase 1/2	-	36	UCB	lkqpakablw(oarbrxqyss) = lnghcmzgfm gbzllhexnm (gneurfbhro, 9 ~ 14) View more	Positive	10 Feb 2019
				comparator	lkqpakablw(oarbrxqyss) = aezjmnaaxb gbzllhexnm (gneurfbhro, 20 ~ 23) View more
NCT03173937 (ASH2018) Manual	Phase 1/2	Anemia, Aplastic	2	Nicotinamide-Expanded Unrelated Cord Blood Transplantation	dkqzuquytt(gjikdizbgm) = At 12 months and 5 months post-transplant, both pts survive with stable engraftment swaydragyv (pqjgurkaxb ) View more	Positive	29 Nov 2018
NCT01816230 (ASCO2016)	Phase 1/2	Hematopoietic stem cell transplantation	16	NiCord	gzxtmbqzzu(rlbbduzeqt) = bjzmnfhyto drzcxipmbu (dymbfmfiyp, 345 - 1512) View more	Positive	20 May 2016
NCT01221857 (Pubmed \| J Clin Invest) Manual	Phase 1/2	Hematologic Neoplasms	11	NiCord	ugwjwlyawi(fkchdjbznd) = hoebeligqa bgooipccwr (nrreplhcdp ) View more	Positive	01 Jul 2014

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis

Omidubicel (Gamida Cell)

Overview

Basic Info

Related

R&D Status

Clinical Result

Translational Medicine

Deal

Core Patent

Clinical Trial

Approval

Regulation